ARTICLE SUMMARY:
Many young companies are working on new approaches to improving infectious disease testing, almost all with an eye toward some of medicine’s most incalcitrant challenges: earlier diagnosis of sepsis and faster susceptibility testing. Several new promising options are available, but so far, none of these is comprehensive and it remains to be seen whether any will be threats to entrenched large companies.
In early December, the CEO of University Hospital, a public hospital in Newark, NJ, resigned after state regulators found major deficiencies in its infection control policies; the hospital had been coping this fall with a deadly outbreak of Acinetobacter baumannii in its NICU in which four infants died.
